期刊文献+

维纳卡兰转复心房颤动有效性及安全性的系统评价 被引量:1

Effectiveness and safety of vernakalant in converting atrial fibrillation
下载PDF
导出
摘要 目的:系统评价维纳卡兰转复心房颤动(房颤)的有效性及安全性。方法检索PubMed、Cochrane Library、中国生物医学文献数据库,收集2000年1月至2013年6月公开发表的关于维纳卡兰治疗房颤[或心房扑动(房扑)]的前瞻性对照研究。按照预先设定的纳入和排除标准选择文献,采用Jadad评分量表对纳入的文献进行质量评价。由两位研究者独立提取纳入文献的资料,使用Revman5.0统计软件进行Meta分析。结果有7篇前瞻性临床研究满足纳入标准。总共1133例房颤(房扑)患者纳入研究(其中维纳卡兰组668例,对照组465例)。Meta分析显示:维纳卡兰组房颤转复率明显高于对照组(38.3%vs.14.1%;OR=5.73;P<0.0001),尤其是在新发房颤患者当中其转复率可达52.2%(95%CI:46.9%~57.4%),中位转复时间为11 min。对于持续房颤维纳卡兰的转复率为8.3%(95%CI:3.1%~13.6%)。房扑终止率为2.6%。尽管维纳卡兰延长QRS波时限和QT间期,但在观察期内未增加主要不良心血管事件风险。结论现有循证医学证据显示维纳卡兰可以安全、有效、快速地转复新发房颤,维纳卡兰对房扑转复效果不显著。 Objective To review systematically the effectiveness and safety of vernakalant in converting atrial fibrillation (AF). Methods The databases of PubMed, Cochrane Library and CBM were retrieved for collecting perspective control studies about treatment of AF (or atrial flutter) were retrieved from Jan. 2000 to Jun. 2013. The studies were selected according to pre-set inclusion and exclusion criteria and then given quality reviews by using Jadad rating scale. The data was extracted by two independent researches from included studies and then given Meta-analysis by using Revman5.0 software. Results There were 7 trials met the inclusion criterion involving 1133 patients (668 in vernakalant group and 465 in control group). The results of Meta-analysis showed that conversion rate was higher in vernakalant group than that in control group (38.3% vs. 14.1%; OR=5.73; P〈0.0001). The conversion rate reached 52.2%(95%CI:46.9%~57.4%) in the patients with new-onset AF and median conversion time was 11 min. The conversion rate was 8.3% (95%CI: 3.1%-13.6%) in the patients with persistent AF. Vernakalant had not significant effect on atrial flutter and the terminating rate was 2.6%only. Although it prolonged QRS duration and QT interval, vernakalant did not increase the risk of major cardiovascular adverse events during observation period. Conclusion The current evidence of evidence-based medicine shows that vernakalant is safe, effective and quick in converting AF.
出处 《中国循证心血管医学杂志》 2014年第1期6-9,共4页 Chinese Journal of Evidence-Based Cardiovascular Medicine
关键词 维纳卡兰 心房颤动 系统评价 Vernakalant Atrial fibrillation Systemic reviewing
  • 相关文献

参考文献1

二级参考文献23

  • 1Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation : analysis and implications. Arch Intern Med,1995,155:469-473.
  • 2Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet, 1999,354 : 1896-1900.
  • 3Hu CL, Jiang H, Tang QZ, et al. Comparison of rate control and rhythm control in patients with atrial fibrillation after percutaneous mitral balloon valvotomy: a randomised controlled study. Heart, 2006,92 : 1096-1101.
  • 4Lee JK, Klein GJ, Krahn AD, et al. Rate-control versus conversion strategy in postoperative atrial fibrillation: trim design and pilot study results. Card Electrophysiol Rev, 2003,7: 178- 184.
  • 5Lee JK, Klein G J, Krahn AD, et al. Rate-control versus conversion strategy in postoperative atrial fibrillation : prospective, randomized pilot study. Am Heart J,2000,140:871- 877.
  • 6Vora A, Kamad D, Goyal V, et al. Control of rate versus rhythm in rheumatic atrial fibrillation: a randomized study. Indian Heart J ,2004,56:110-116.
  • 7Vora A, Karnad D, Goyal V, et al. Control of heart rate versusrhythm in rheumatic atrial fibrillation: a randomized study. J Cardiovasc Pharmacol Ther,2004 ,9 :65-73.
  • 8Yildiz A, Yigit Z, Okcnn B, et al. Comparison of rate and rhythm control in hypertension patients with atrial fibrillation. Circ J, 2008,72:705-708.
  • 9Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med ,2002,347 : 1825-1833.
  • 10Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-pharmacological intervention in atrial fibrillation (PIAF) : a randomised trial. Lancet,2000,356 : 1789-1794.

共引文献8

同被引文献31

  • 1唐哨勇,王世敏,蒋学俊.电压依赖性Kv1.5通道的研究进展[J].国外医学(心血管疾病分册),2004,31(5):262-264. 被引量:6
  • 2邓玉莲,高峰,许春萱,张建成,陈林.心房颤动患者心房组织延迟整流钾通道基因表达的研究[J].中华心律失常学杂志,2005,9(6):445-448. 被引量:9
  • 3Stump GL, Wallace AA, Regan CP, et al. In vivo antiarrhythmic and cardiac eleetrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5 -methylcyclohexyl) diphenylphosphine oxide[J]. J Pharmacol Exp Ther, 2005, 315(3): 1362-1367.
  • 4Kom SJ, Horn R. Nordihydroguaiaretic acid inhibits voltage-activated Ca2+ currents independently of lipo-oxygenase inhibition [J]. Molecular Pharmacology, 1990, 38(4): 524.
  • 5Knobloch K, Brendel J, Peukert S, et al. Electrophysiological and antiarrhythmic effects of the novel IKur channel blockers, S9947 and S20951, on leit vs. right pig atrium in vivo in comparison with the I (kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide[J]. Naunyn Schmiedebergs Arch Pharmacol, 2002, 366(5): 482-487.
  • 6刘泰桂.心肌细胞电生理学[M].北京:北京大学出版社,2005.
  • 7Olson TM, Alekseev AE, Liu XK, et al. Kv1.5 channelopathy due to KCNA5 loss- of-function mutation causes human atrial fibrillation[J]. Hum Mol Genet, 2006, 15(14): 2185-2191.
  • 8Trapan JG, Kom SJ. Effect of External pH on Activation of the Kvl.5 Potassium Channel[J]. Biophysical, 2003, 84(1): 195-204.
  • 9Yamashita T, Murakawa Y, Hayami N, et al. short-term effects of rapid atrial pacing on mRNA level of voltage-dependent K+channels in rat atrium:electrical remodelling in paroxysmal atrial tachycardia [J]. Circulation, 2000, 101(16): 2007-2014.
  • 10Lai LP, Su MJ, Lin JL, et al. Changes in the mRNA levels of delayed rectifier Potassium channels in human atrial fibrillation [J].Cardiology, 1999, 92(4): 248-255.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部